A model building exercise of mortality risk for Taiwanese women with breast cancer

Table 3 Description of the population by univariate logistic regression test using the pathological data

	Pathological Data
Risk factors	Mortality(%)	Odds Ratio	P-value
Pathological report		<.001 (a v.s. c)	N.S.
		0.532 (b v.s. c)	N.S.
Others (a) (n = 138)	0
Invasive ductal carcinoma (b) (n = 966)	66 (6.8%)
Invasive lobular carcinoma (c) (n = 33)	4 (12.1%)
Tumor grade		2.172	<.0001 *
III (n = 234)	27 (11.5%)
II (n = 431)	24 (5.6%)
I (n = 294)	8 (2.7%)
ER/PR		1.99	0.009 *
(-, -), (-, +), (+, -) (n = 583)	47 (8.1%)
(+, +) (n = 545)	23 (4.2%)
Her-2/Neu		2.125	0.014*
+++ (n = 181)	18 (9.9%)
-, +, ++ (n = 668)	33 (4.9%)
EIC		2.036	0.032 *
Absent (n = 590)	46 (7.8%)
Present (n = 301)	12 (4.0%)
LTE		2.856	0.0004 *
Present (n = 501)	46 (9.2%)
Absent (n = 468)	16 (3.4%)
HBsAg		1.22	N.S.
+ (n = 124)	8 (6.5%)
- (n = 598)	32 (5.4%)
HCVAb		1.103	N.S.
+ (n = 50)	3 (6%)
- (n = 658)	36 (5.5%)
R/T		1.002	N.S.
Yes (n = 581)	39 (6.7%)
No (n = 552)	31 (5.6%)
Anti-hormone therapy		1.002	N.S.
No (n = 228)	14 (6.2%)
Yes (n = 909)	56 (6.2%)
Tumor size		2.579	<.0001 *
T4 (n = 57)	10 (17.5%)
T2 or T3 (n = 595)	45 (7.6%)
Tis or T1 (n = 485)	15 (3.1%)
Node		4.053	<.0001 *
N3 (n = 81)	23 (28.4%)
N1 or N2 (n = 377)	31 (8.2%)
N0 (n = 677)	16 (2.4%)
Chemotherapy		0.061 (a v.s. c)	<0.0001*
		0.391 (b v.s. c)	0.009 *
No (a) (n = 327)	4 (1.2%)
Yes (b) (n = 745)	55 (7.4%)
Abandonment or Refusal (c) (n = 65)	11 (18%)

ISSN: 1472-6947